|
 |
 |  |
Diabetes Drug as a Potential Treatment for Cancer
An article in the September 15, 2009, on-line edition of the Wall Street Journal
discusses the potential use of Metformin as a new cancer treatment. In the highlighted
study, low doses of Metformin combined with Doxorubicin, a widely used chemotherapeutic
drug, shrank breast-cancer tumors in mice and prevented their reoccurrence more
effectively than Doxorubicin alone. (Wall Street Journal)
Researchers at Harvard Medical School, in a study published in the October 1 edition
of the journal Cancer Research, demonstrated that the combination of Metformin and
Doxorubicin killed both regular cancer cells and cancer stem cells in mice. Mice
with tumors generated from human breast-cancer cells remained tumor-free for nearly
three months on the combined treatment whereas tumors reoccurred in the mice given
Doxorubicin only.
Several other recent studies have also shown Metformin’s potential against cancer.
For example, one study from the M.D. Anderson Cancer Center found that diabetic
patients treated with Metformin were less likely to develop pancreatic cancer than
those not on the diabetic drug. Findings from these studies support the possible
benefit of additional trials to evaluate the effectiveness of Metformin with other
chemotherapeutic drugs in the treatment of cancer.
Cerilliant offers a certified solution standard of Metformin (M-072)
and also provides certified reference standards of drugs used in cancer treatment,
including taxanes such as
Paclitaxel, Taxol, Baccatin III, and 10-Deacetylbaccatin III. Click on the
link below to view these featured reference standards:
Cerilliant Certified Reference
Standard of Metformin
Cerilliant Certified Reference
Standards of Taxanes
Return to Article List
|
|
|
|